Marko Lucijanic1, David Cicic2, Tajana Stoos-Veic3,4, Vlatko Pejsa2,5, Jelena Lucijanic6, Amina Fazlic Dzankic2,7, Josipa Vlasac Glasnovic2, Ena Soric2, Marko Skelin8, Rajko Kusec2,5,9. 1. Hematology Department, University Hospital Dubrava, Zagreb, Croatia markolucijanic@yahoo.com. 2. Hematology Department, University Hospital Dubrava, Zagreb, Croatia. 3. Department of Clinical Cytology and Cytometry, University Hospital Dubrava, Zagreb, Croatia. 4. Faculty of Medicine, University of Osijek, Osijek, Croatia. 5. School of Medicine, University of Zagreb, Zagreb, Croatia. 6. Health Care Center Zagreb-West, Zagreb, Croatia. 7. Hematology Department, General Hospital Sisak, Sisak, Croatia. 8. Pharmacy Department, General Hospital Sibenik, Sibenik, Croatia. 9. Divison of Molecular Diagnosis and Genetics, Clinical Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia.
Abstract
BACKGROUND/AIM: We aimed to investigate clinical associations of inflammatory biomarkers neutrophil-to-lymphocyte-ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in patients with myelofibrosis, myeloproliferative neoplasm with inflammatory background. PATIENTS AND METHODS: We retrospectively analyzed a cohort of 102 myelofibrosis patients. NLR and PLR were assessed in addition to other disease-specific parameters. RESULTS: NLR and PLR were significantly higher in myelofibrosis than in healthy controls. Higher NLR was significantly associated with Janus-kinase-2 (JAK2)-mutation, wild-type-Calreticulin (CALR), older age and parameters reflecting increased proliferative potential of disease (higher leukocytes, higher hemoglobin, larger spleen-size), whereas there was no significant association with C-reactive-protein (CRP). Higher PLR was significantly associated with absence of blast-phase-disease, absence of constitutional-symptoms, lower percentage-of-circulatory-blasts, smaller spleen-size and lower CRP. In the Cox-regression-model, higher-NLR (HR=2.76; p=0.004), lower-PLR (HR=1.99; p=0.042) and Dynamic-International-Prognostic-System (DIPSS) (HR=3.26; p<0.001) predicted inferior survival independently of each other. CONCLUSION: In the context of myelofibrosis, elevated NLR and PLR are more likely to represent myeloproliferation itself and not necessary the extent of inflammation. Copyright
BACKGROUND/AIM: We aimed to investigate clinical associations of inflammatory biomarkers neutrophil-to-lymphocyte-ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in patients with myelofibrosis, myeloproliferative neoplasm with inflammatory background. PATIENTS AND METHODS: We retrospectively analyzed a cohort of 102 myelofibrosispatients. NLR and PLR were assessed in addition to other disease-specific parameters. RESULTS: NLR and PLR were significantly higher in myelofibrosis than in healthy controls. Higher NLR was significantly associated with Janus-kinase-2 (JAK2)-mutation, wild-type-Calreticulin (CALR), older age and parameters reflecting increased proliferative potential of disease (higher leukocytes, higher hemoglobin, larger spleen-size), whereas there was no significant association with C-reactive-protein (CRP). Higher PLR was significantly associated with absence of blast-phase-disease, absence of constitutional-symptoms, lower percentage-of-circulatory-blasts, smaller spleen-size and lower CRP. In the Cox-regression-model, higher-NLR (HR=2.76; p=0.004), lower-PLR (HR=1.99; p=0.042) and Dynamic-International-Prognostic-System (DIPSS) (HR=3.26; p<0.001) predicted inferior survival independently of each other. CONCLUSION: In the context of myelofibrosis, elevated NLR and PLR are more likely to represent myeloproliferation itself and not necessary the extent of inflammation. Copyright
Authors: Ivan Krečak; Hrvoje Holik; Martina Morić Perić; Ivan Zekanović; Božena Coha; Velka Gverić-Krečak; Marko Lucijanić Journal: Wien Klin Wochenschr Date: 2022-04-07 Impact factor: 1.704
Authors: Cosmin Citu; Florin Gorun; Andrei Motoc; Ioan Sas; Oana Maria Gorun; Bogdan Burlea; Ioana Tuta-Sas; Larisa Tomescu; Radu Neamtu; Daniel Malita; Ioana Mihaela Citu Journal: Diagnostics (Basel) Date: 2022-01-06